Publications

Publication Search

Search for publications by

Molecular engineering of therapeutic cytokines

Abstract

Over the past three decades, a large body of work has been directed at the development of therapeutic cytokines. Despite their central role in immune modulation, only a handful of cytokine therapeutics has achieved regulatory approval. One of the major challenges associated with the therapeutic use of cytokines relates to their short serum half-life and low bioavailability. High doses are required to overcome these problems, which often result in dose-limiting toxicities. Consequently, most cytokines require protein engineering approaches to reduce toxicity and increase half-life. For this purpose, PEGylation, fusion proteins, antibody complexes and mutagenesis have been utilized. Here, we summarize past, recent and emerging strategies in this area.

Type Journal
Authors Vazquez-Lombardi, R.; Roome, B.; Christ, D.
Garvan Authors A/Prof Daniel Christ , Rodrigo Vazquez-Lombardi
Publisher Name Antibodies
Published Date 2013-08-01 00:00:00
Published Volume 2
Published Pages 426-451
URL http://www.mdpi.com/2073-4468/2/3/426
Status Published In-print
OpenAccess Link https://publications.gimr.garvan.org.au/download.php?11852_12404/13_VazquezLombardi_Antibodies_.pdf